{"abstract": "The British drug maker said it would initially pay $875 million for the rights to the drugs, and up to $1.22 billion more if development and sales milestones are met.", "web_url": "https://dealbook.nytimes.com/2014/07/30/astrazeneca-to-pay-up-to-2-1-billion-for-respiratory-drugs/", "snippet": "The British drug maker said it would initially pay $875 million for the rights to the drugs, and up to $1.22 billion more if development and sales milestones are met.", "lead_paragraph": "Updated, 9:30 a.m. | LONDON \u2013 AstraZeneca of Britain said on Wednesday that it had agreed to pay up to $2.1 billion for a slate of respiratory drugs from the Spanish drug maker Almirall.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "AstraZeneca to Pay Almirall Up to $2.1 Billion for Respiratory Drugs", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Chronic Obstructive Pulmonary Disease", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 4, "major": "N"}, {"name": "subject", "value": "Respiratory Diseases", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Almirall SA", "rank": 6, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 7, "major": "N"}, {"name": "organizations", "value": "Baxter International", "rank": 8, "major": "N"}, {"name": "organizations", "value": "GlaxoSmithKline PLC", "rank": 9, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 10, "major": "N"}], "pub_date": "2014-07-30T09:20:13+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/3500a053-4cec-5aee-b1d3-88db49252df6", "word_count": 356, "uri": "nyt://article/3500a053-4cec-5aee-b1d3-88db49252df6"}